Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | May 03, 2021 | May 10, 2021 |
| Invivyd, Inc.ADGI · Entity 721 | Chief Financial Officer | January 30, 2022 | February 01, 2022 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Sr. V.P. & CFO, Corp. Dev. | March 22, 2018 | March 26, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date May 03, 2021 · Filed May 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2031-05-03 | Direct | 92,500 |
Reported balance
After 2021-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-03 · Grant · Acquired 92,500 · Balance 92,500 F1: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis.
Invivyd, Inc.
Report date January 30, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2032-01-29 | Direct | 175,000 |
Reported balance
After 2022-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-30 · Grant · Acquired 175,000 · Balance 175,000 F1: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
Voyager Therapeutics, Inc.
Report date March 22, 2018 · Filed March 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-03-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-03-22 · Exercise / conversion · Acquired 19,900 · Balance 19,900 Row 2 · 2018-03-22 · Sale · Disposed 19,900 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Row 3 · 2018-03-23 · Exercise / conversion · Acquired 11,200 · Balance 11,200 Row 4 · 2018-03-23 · Sale · Disposed 11,200 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97 · Expires 2027-01-03 | Direct | 176,784 |
Reported balance
After 2018-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-22 · Exercise / conversion · Disposed 19,900 · Balance 176,784 F3: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97 · Expires 2027-01-03 | Direct | 165,584 |
Reported balance
After 2018-03-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-23 · Exercise / conversion · Disposed 11,200 · Balance 165,584 F3: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 9,398 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2034-06-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 26,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.83 · Expires 2033-06-23 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2032-06-02 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.32 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.20 · Expires 2030-06-01 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2029-04-03 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 11,797 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo.
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 158,371 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 175,345 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 124,962 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 83,690 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
CARGO Therapeutics, Inc.
Report date August 19, 2025 · Filed August 19, 2025
Section 16 reporting ended · disclosed 2025-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2025-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
IVERIC bio, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 1
1 source rowRow 1 · 2023-07-11 · Disposition to issuer · Disposed 22,088 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.85 · Expires 2028-01-12 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-11 · Disposition to issuer · Disposed 32,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2029-05-14 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2030-06-08 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-05-18 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-07-11 · Disposition to issuer · Disposed 15,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.94 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-07-11 · Disposition to issuer · Disposed 23,186 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 83,690 | Not disclosed Strike: $75.78 | Not disclosed |
DisclosureSEC source: 0001140361-26-035611 · form4.xml · derivative · entry 4 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,690 shares Expires 2036-01-02 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 124,962 | Not disclosed Strike: $49.07 | Not disclosed |
DisclosureSEC source: 0001140361-26-035611 · form4.xml · derivative · entry 3 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,962 shares Expires 2034-12-09 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 175,345 | Not disclosed Strike: $22.86 | Not disclosed |
DisclosureSEC source: 0001140361-26-035611 · form4.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,345 shares Expires 2033-12-18 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerCommon Stock | 158,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-035611 · form4.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. F1 · price: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. Read SEC document |
| July 24, 2026 Filed Jul 25, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-086729 · tm2621304-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,371 F1 · kind: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 289 | $83.16 | $24,033.24 |
DisclosureSEC source: 0001104659-26-055091 · tm2613425-1_4seq1.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 900 | $82.60 | $74,340.00 |
DisclosureSEC source: 0001104659-26-055091 · tm2613425-1_4seq1.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,660 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 811 | $81.02 | $65,707.22 |
DisclosureSEC source: 0001104659-26-055091 · tm2613425-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,560 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 16, 2026 Filed Apr 18, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,000 | $90.00 | $180,000.00 |
DisclosureSEC source: 0001104659-26-045062 · tm2612090-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,100 | $85.46 | $94,006.00 |
DisclosureSEC source: 0001104659-26-039708 · tm2611042-2_4seq1.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.17 to $85.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 900 | $84.46 | $76,014.00 |
DisclosureSEC source: 0001104659-26-039708 · tm2611042-2_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,471 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.15 to $85.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 25, 2026 Filed Mar 28, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,000 | $85.00 | $170,000.00 |
DisclosureSEC source: 0001104659-26-036332 · tm269945-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 406 | $71.66 | $29,093.96 |
DisclosureSEC source: 0001104659-26-023651 · tm267888-1_4seq1.xml · nonDerivative · entry 4 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.04 to $71.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 994 | $70.45 | $70,027.30 |
DisclosureSEC source: 0001104659-26-023651 · tm267888-1_4seq1.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,777 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 300 | $69.43 | $20,829.00 |
DisclosureSEC source: 0001104659-26-023651 · tm267888-1_4seq1.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,771 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.91 to $69.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 300 | $68.27 | $20,481.00 |
DisclosureSEC source: 0001104659-26-023651 · tm267888-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,071 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.77 to $68.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 100 | $66.89 | $6,689.00 |
DisclosureSEC source: 0001104659-26-010453 · tm265045-1_4seq1.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,108 | $66.15 | $73,294.20 |
DisclosureSEC source: 0001104659-26-010453 · tm265045-1_4seq1.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,471 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.84 to $66.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 792 | $65.21 | $51,646.32 |
DisclosureSEC source: 0001104659-26-010453 · tm265045-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,579 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,000 | $80.00 | $160,000.00 |
DisclosureSEC source: 0001104659-26-001483 · tm261906-1_4seq1.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 83,690 | $0.00 Strike: $75.78 | $0.00 |
DisclosureSEC source: 0001104659-26-001483 · tm261906-1_4seq1.xml · derivative · entry 4 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,690 Underlying: Common Stock · 83,690 shares Expires 2036-01-02 F4 · derivative.exercise_date: This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 4,080 | $75.20 | $306,816.00 |
DisclosureSEC source: 0001104659-26-001483 · tm261906-1_4seq1.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.73 to $75.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,920 | $74.13 | $142,329.60 |
DisclosureSEC source: 0001104659-26-001483 · tm261906-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,451 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.67 to $74.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,500 | $80.00 | $120,000.00 |
DisclosureSEC source: 0001104659-25-124354 · tm2534063-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,797 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · derivative · entry 7 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,797 shares Expires 2029-04-03 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | Not disclosed Strike: $25.20 | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · derivative · entry 6 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2030-06-01 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | Not disclosed Strike: $26.32 | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · derivative · entry 5 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2031-06-01 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $8.13 | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · derivative · entry 4 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-06-02 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $50.83 | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · derivative · entry 3 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-06-23 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $23.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2034-06-08 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Read SEC document |
| December 09, 2025 Filed Dec 9, 2025 10:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Disposition to issuerCommon Stock | 9,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-312098 · ownership.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. F2 · shares: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,500 | $75.00 | $112,500.00 |
DisclosureSEC source: 0001104659-25-118985 · tm2532835-2_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,871 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. Read SEC document |
| November 25, 2025 Filed Nov 29, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,500 | $70.00 | $105,000.00 |
DisclosureSEC source: 0001104659-25-117036 · tm2532308-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,000 | $65.00 | $130,000.00 |
DisclosureSEC source: 0001104659-25-112825 · tm2531402-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,871 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 01:37 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,000 | $60.00 | $60,000.00 |
DisclosureSEC source: 0001104659-25-111631 · tm2531086-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,871 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 20:42 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.35 | Not disclosed |
DisclosureSEC source: 0001610717-25-000301 · form4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2035-06-17 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · price: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · price: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 20:32 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0000950170-25-107545 · ownership.xml · derivative · entry 3 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,797 Underlying: Common Stock · 3,000 shares Expires 2029-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 20:32 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,000 | $47.46 | $142,371.00 |
DisclosureSEC source: 0000950170-25-107545 · ownership.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,398 Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 20:32 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 3,000 | $7.01 | $21,027.00 |
DisclosureSEC source: 0000950170-25-107545 · ownership.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:39 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001610717-25-000244 · form4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:07 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 9,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-082311 · ownership.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,398 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 124,962 | $0.00 Strike: $49.07 | $0.00 |
DisclosureSEC source: 0001104659-24-127705 · tm2430773-2_4seq1.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,962 Underlying: Common Stock · 124,962 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option represents the right to purchase 124,962 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 23, 2024 Filed Aug 24, 2024 00:05 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 6,000 | $48.26 | $289,560.00 |
DisclosureSEC source: 0001104659-24-092519 · tm2422592-1_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,871 Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 17:24 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $23.02 | $0.00 |
DisclosureSEC source: 0000950170-24-072066 · ownership.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-06-07 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:26 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 39,402 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001610717-24-000297 · form4.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,402 Underlying: Common Stock · 39,402 shares Expires 2034-06-03 F2 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on each monthly anniversary measured from June 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:26 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 19,785 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001610717-24-000297 · form4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,785 Underlying: Common Stock · 19,785 shares Expires 2034-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the "Vesting Commencement Date") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 18, 2023 Filed Dec 21, 2023 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 175,345 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-23-127820 · tm2333399-2_4seq1.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,345 Underlying: Common Stock · 175,345 shares Expires 2033-12-18 F1 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,186 | Not disclosed Strike: $9.94 | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 8 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,186 shares Expires 2032-05-11 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,500 | Not disclosed Strike: $6.82 | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 7 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2031-05-18 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,000 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 6 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2030-06-08 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.